JP5861242B2 - クラステリンのペプチドリガンド及びその使用 - Google Patents

クラステリンのペプチドリガンド及びその使用 Download PDF

Info

Publication number
JP5861242B2
JP5861242B2 JP2012505008A JP2012505008A JP5861242B2 JP 5861242 B2 JP5861242 B2 JP 5861242B2 JP 2012505008 A JP2012505008 A JP 2012505008A JP 2012505008 A JP2012505008 A JP 2012505008A JP 5861242 B2 JP5861242 B2 JP 5861242B2
Authority
JP
Japan
Prior art keywords
peptide
clusterin
imaging
tumor
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012505008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524029A5 (enExample
JP2012524029A (ja
Inventor
ラナ フィルフィル，
ラナ フィルフィル，
ドミトリ トルカチェフ，
ドミトリ トルカチェフ，
フェン ニ，
フェン ニ，
モーリーン， ディー． オコナー−マコート，
モーリーン， ディー． オコナー−マコート，
アン， イー．， ジー． レンフェリンク，
アン， イー．， ジー． レンフェリンク，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Publication of JP2012524029A publication Critical patent/JP2012524029A/ja
Publication of JP2012524029A5 publication Critical patent/JP2012524029A5/ja
Application granted granted Critical
Publication of JP5861242B2 publication Critical patent/JP5861242B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
JP2012505008A 2009-04-17 2010-04-15 クラステリンのペプチドリガンド及びその使用 Active JP5861242B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20291009P 2009-04-17 2009-04-17
US61/202,910 2009-04-17
PCT/CA2010/000566 WO2010118521A1 (en) 2009-04-17 2010-04-15 Peptide ligands for clusterin and uses thereof

Publications (3)

Publication Number Publication Date
JP2012524029A JP2012524029A (ja) 2012-10-11
JP2012524029A5 JP2012524029A5 (enExample) 2013-05-30
JP5861242B2 true JP5861242B2 (ja) 2016-02-16

Family

ID=42982086

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012505008A Active JP5861242B2 (ja) 2009-04-17 2010-04-15 クラステリンのペプチドリガンド及びその使用

Country Status (6)

Country Link
US (1) US8629240B2 (enExample)
EP (1) EP2419440B1 (enExample)
JP (1) JP5861242B2 (enExample)
AU (1) AU2010237569B2 (enExample)
CA (1) CA2756570C (enExample)
WO (1) WO2010118521A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063523A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
CN110312549B (zh) * 2016-12-19 2021-06-29 莫尔豪斯医学院 用于通过抑制外泌体释放来治疗疾病的组合物和方法
US11180534B1 (en) 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections
CN119874833A (zh) * 2025-01-14 2025-04-25 广州中医药大学(广州中医药研究院) Clusterin亲和肽及其修饰的长循环纳米粒的制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9312598A (en) * 1997-09-10 1999-03-29 Allegheny University Of The Health Sciences Inhibitors of collagen assembly
AU748700B2 (en) * 1998-06-12 2002-06-13 Aventis Pasteur HIV virus mimotopes
US6348185B1 (en) * 1998-06-20 2002-02-19 Washington University School Of Medicine Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20050208558A1 (en) * 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
ITRM20040098A1 (it) * 2004-02-25 2004-05-25 Univ Roma Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
JP5376948B2 (ja) * 2005-09-13 2013-12-25 ナショナル リサーチ カウンシル オブ カナダ 腫瘍細胞活性を調節する方法及び組成物
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers

Also Published As

Publication number Publication date
EP2419440A4 (en) 2013-04-03
EP2419440B1 (en) 2015-11-11
US8629240B2 (en) 2014-01-14
EP2419440A1 (en) 2012-02-22
AU2010237569A1 (en) 2011-11-10
US20120121507A1 (en) 2012-05-17
CA2756570C (en) 2019-04-30
JP2012524029A (ja) 2012-10-11
AU2010237569B2 (en) 2015-04-02
CA2756570A1 (en) 2010-10-21
WO2010118521A1 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
Zhu et al. Novel glypican-3-binding peptide for in vivo hepatocellular carcinoma fluorescent imaging
JP5861242B2 (ja) クラステリンのペプチドリガンド及びその使用
KR102306065B1 (ko) 올리고펩티드 및 그 결합체를 생산하는 방법
US12465660B2 (en) Compositions and methods for cancer imaging and radiotherapy
CN107001417A (zh) 靶向肽及其使用方法
KR102318408B1 (ko) 올리고펩티드 및 그 결합체를 생산하는 방법
CN108623661A (zh) 一种靶向胰腺癌肿瘤细胞的双特异性多肽分子探针及应用
Biscaglia et al. PreS1 peptide-functionalized gold nanostructures with SERRS tags for efficient liver cancer cell targeting
Huang et al. Dual-modality micro-positron emission tomography/computed tomography and near-infrared fluorescence imaging of EphB4 in orthotopic glioblastoma xenograft models
CN103491983B (zh) 与心血管成像相关的材料及方法
Cao et al. Development of a novel HER2-targeted peptide probe for dual-modal imaging of tumors
Leitao et al. Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity
US20080031815A1 (en) Pet imaging of vascular endothelial growth factor receptor (VEGFR), compositions for VEGF cancer imaging, and methods of VEGF cancer imaging
Feng et al. Multi-modal imaging probe for glypican-3 overexpressed in orthotopic hepatocellular carcinoma
Wu et al. Multi-modal imaging for uptake of peptide ligand specific for CD44 by hepatocellular carcinoma
JP2022546422A (ja) 前立腺特異的膜抗原（ｐｓｍａ）を標的化するための単一ドメイン抗体
Daquinag et al. Fibulin-4 is highly expressed in metastatic breast cancer and can serve as a target of peptide-based imaging probes and experimental therapeutics
Xu et al. TMVP1446/GS5, a novel peptide with improved metabolic stability relative to TMVP1446, targets VEGFR-3 for primary tumor and lymph node metastases detection in vivo
CN120550151A (zh) 一种检测胶原结构变性的放射性核素标记分子探针及其制备方法与应用
Anderson et al. AACR/SNMMI State-of-the-Art Molecular Imaging in Cancer Biology and Therapy: Abstracts
Huang Applications Of Ephb4 Receptor Specific Peptides In Targeted Cancer Imaging And Therapy
EA042953B1 (ru) Композиции и способы для визуализации и лучевой терапии рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151023

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151204

R150 Certificate of patent or registration of utility model

Ref document number: 5861242

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250